Dysregulated lipid metabolism links NAFLD to cardiovascular disease
A Deprince, JT Haas, B Staels - Molecular metabolism, 2020 - Elsevier
Background Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming a global health
problem. Cardiovascular diseases (CVD) are the most common cause of mortality in NAFLD …
problem. Cardiovascular diseases (CVD) are the most common cause of mortality in NAFLD …
Alcohol-associated liver disease
B Mackowiak, Y Fu, L Maccioni… - The Journal of Clinical …, 2024 - Am Soc Clin Investig
Alcohol-associated liver disease (ALD) is a major cause of chronic liver disease worldwide,
and comprises a spectrum of several different disorders, including simple steatosis …
and comprises a spectrum of several different disorders, including simple steatosis …
Multiomics study of nonalcoholic fatty liver disease
G Sveinbjornsson, MO Ulfarsson, RB Thorolfsdottir… - Nature …, 2022 - nature.com
Nonalcoholic fatty liver (NAFL) and its sequelae are growing health problems. We performed
a genome-wide association study of NAFL, cirrhosis and hepatocellular carcinoma, and …
a genome-wide association study of NAFL, cirrhosis and hepatocellular carcinoma, and …
Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is common and partially heritable and has no
effective treatments. We carried out a genome-wide association study (GWAS) meta …
effective treatments. We carried out a genome-wide association study (GWAS) meta …
Large-scale genome-wide association study of coronary artery disease in genetically diverse populations
We report a genome-wide association study (GWAS) of coronary artery disease (CAD)
incorporating nearly a quarter of a million cases, in which existing studies are integrated with …
incorporating nearly a quarter of a million cases, in which existing studies are integrated with …
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …
population, and has no approved drug therapy. Although pharmacotherapies are in …
[PDF][PDF] Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study
L Chen, H Yang, H Li, C He, L Yang, G Lv - Hepatology, 2022 - Wiley Online Library
Abstract Background and Aims The risk factors of cholelithiasis have not been clearly
identified, especially for total cholesterol. Here, we try to identify these causal risk factors …
identified, especially for total cholesterol. Here, we try to identify these causal risk factors …
[HTML][HTML] Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
K Pafili, M Roden - Molecular Metabolism, 2021 - Elsevier
Background Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with
increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic …
increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic …
[HTML][HTML] Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆
Background & Aims Genetic factors associated with non-alcoholic fatty liver disease
(NAFLD) remain incompletely understood. To date, most genome-wide association studies …
(NAFLD) remain incompletely understood. To date, most genome-wide association studies …
Past, present and future perspectives in nonalcoholic fatty liver disease
AJ Sanyal - Nature reviews Gastroenterology & hepatology, 2019 - nature.com
Nonalcoholic fatty liver disease (NAFLD) was first described as a distinct clinical entity four
decades ago. However, the condition has become the centre of attention within hepatology …
decades ago. However, the condition has become the centre of attention within hepatology …